Coherus BioSciences laying off 20% of employees
Abu Hanifah
- Coherus BioSciences (NASDAQ:CHRS) will lay off 20% of its workforce -- about 60 full-time and part-time employees -- on Friday.
- The biotech said the cuts would allow it to focus resources on strategic priorities such as commercialization of its product portfolio and development of its immuno-oncology pipeline.
- The disclosure came in the biotech's latest 10-K filing.
- In its Q4 earnings report released on Monday, Coherus (CHRS) beat on the bottom line but missed on the top.